Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
1.110
-0.060 (-5.13%)
Feb 6, 2025, 4:00 PM EST - Market closed
Prelude Therapeutics Employees
Prelude Therapeutics had 128 employees as of December 31, 2023. The number of employees increased by 6 or 4.92% compared to the previous year.
Employees
128
Change (1Y)
6
Growth (1Y)
4.92%
Revenue / Employee
$23,438
Profits / Employee
-$1,027,477
Market Cap
61.09M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 128 | 6 | 4.92% |
| Dec 31, 2022 | 122 | 6 | 5.17% |
| Dec 31, 2021 | 116 | 48 | 70.59% |
| Dec 31, 2020 | 68 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
PRLD News
- 2 months ago - Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies - GlobeNewsWire
- 2 months ago - Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit - GlobeNewsWire
- 3 months ago - Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium - GlobeNewsWire
- 4 months ago - Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium - GlobeNewsWire
- 5 months ago - Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial - GlobeNewsWire
- 5 months ago - Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024 - GlobeNewsWire
- 6 months ago - Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers - GlobeNewsWire